We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · March 03, 2021

HER2-Targeted Therapy Prolongs Survival in Patients With HER2+ Breast Cancer and Intracranial Metastatic Disease

Neuro-Oncology Advances

 

Additional Info

Neuro-Oncology Advances
HER2-Targeted Therapy Prolongs Survival in Patients With HER2-Positive Breast Cancer and Intracranial Metastatic Disease: A Systematic Review and Meta-Analysis
Neurooncol Adv 2020 Oct 14;2(1)vdaa136, AW Erickson, F Ghodrati, S Habbous, KJ Jerzak, A Sahgal, MS Ahluwalia, S Das

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading